MARKET

ADMP

ADMP

Adamis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.275
+0.035
+2.82%
Opening 12:59 02/24 EST
OPEN
1.230
PREV CLOSE
1.240
HIGH
1.322
LOW
1.160
VOLUME
4.57M
TURNOVER
--
52 WEEK HIGH
2.340
52 WEEK LOW
0.2700
MARKET CAP
171.10M
P/E (TTM)
-2.5633
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adamis Pharma (ADMP) Receives a Hold from Raymond James
Raymond James analyst Elliot Wilbur maintained a Hold rating on Adamis Pharma (ADMP) today. The company's shares closed last Monday at $1.35. According to
SmarterAnalyst · 1d ago
Adamis gets FDA greenlight for tempol human studies in COVID-19
Adamis Pharmaceuticals ([[ADMP]] +5.1%) announces that the U.S. FDA has given it the go ahead for the Investigational New Drug ((IND)) application and proposed clinical trial of Tempol for the
Seekingalpha · 2d ago
DJ Adamis Pharmaceuticals Shares Rise 10% After FDA Completes Safety Review
Dow Jones · 2d ago
Adampis Pharmaceuticals Says Cleared To Proceed With Human Studies Of Tempol For Treatment Of COVID-19
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19 SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Benzinga · 2d ago
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP)...
GlobeNewswire · 2d ago
Epinephrine Auto-Injector Market 2021 : Latest Industry Trends, Growth, Share, Size and 2026 Forecast Research Report with Top countries Data
Feb 22, 2021 (The Expresswire) -- According to 360 Research Reports, the “Epinephrine Auto-Injector Market" 2021 by Types (0.15mg epinephrine auto injector,...
The Express Wire · 2d ago
Allergic Rhinitis Drugs Market Research With Method, Top Companies, Global Development Factors,and Forecast 2026
Feb 22, 2021 (Heraldkeepers) -- The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview...
Heraldkeepers · 2d ago
Allergy Immunotherapy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 22, 2021 (Market Insight Reports) -- The Global Allergy Immunotherapy Market is estimated to value over USD 3.1 billion by 2027 end with a CAGR of over...
Market Insight Reports · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMP. Analyze the recent business situations of Adamis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMP stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 8.45M
% Owned: 6.29%
Shares Outstanding: 134.20M
TypeInstitutionsShares
Increased
12
717.12K
New
12
-1.09M
Decreased
6
415.26K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.29%
Pharmaceuticals & Medical Research
+1.41%
Key Executives
Chairman/Independent Director
Richard Williams
Chief Executive Officer/President/Director
Dennis Carlo
Chief Financial Officer/Senior Vice President - Finance
Robert Hopkins
Senior Vice President/Director
David Marguglio
Vice President - Operations
Karen Daniels
Other
Ronald Moss
Independent Director
Howard Birndorf
Independent Director
Roshawn Blunt
  • Dividends
  • Splits
  • Insider Activity
No Data
About ADMP
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Webull offers kinds of Adamis Pharmaceuticals Corp stock information, including NASDAQ:ADMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMP stock methods without spending real money on the virtual paper trading platform.